	US 12,105,095 B2
	Assay to detect and quantitate specific antibodies for various redox forms of HMGB1
Marie-Lise Gougeon, Antony (FR); Nicole Prada, Paris (FR); and Hela Saidi, Villejuif (FR)
Assigned to INSTITUT PASTEUR, Paris (FR)
Filed by INSTITUT PASTEUR, Paris (FR)
Filed on Jun. 24, 2022, as Appl. No. 17/848,804.
Application 17/848,804 is a division of application No. 15/771,182, granted, now 11,460,473, previously published as PCT/EP2016/076607, filed on Nov. 3, 2016.
Claims priority of application No. 15306747 (EP), filed on Nov. 3, 2015.
Prior Publication US 2022/0317131 A1, Oct. 6, 2022
Int. Cl. G01N 33/53 (2006.01); G01N 33/68 (2006.01)

CPC G01N 33/6854 (2013.01) [G01N 2333/4703 (2013.01); G01N 2800/24 (2013.01); G01N 2800/26 (2013.01); G01N 2800/28 (2013.01); G01N 2800/2814 (2013.01); G01N 2800/50 (2013.01); G01N 2800/56 (2013.01)]

6 Claims

1. An in vitro method for assessing the state of progression of a human immunodeficiency virus (HIV) infection, comprising quantitating specific antibodies for two redox forms of High mobility group box 1 (HMGB1), in a biological sample obtained from a human subject with an HIV infection, by a method comprising;

a) contacting said biological sample with two redox forms of HMGB1, wherein said biological sample is cerebrospinal fluid blood, plasma, or serum; and

b) quantitating the specific antibodies for the two redox forms of HMGB1;

wherein the redox forms of HMGB1 are disulfide-HMGB1 having a disulfide bridge between cysteine residues at positions 23 and 45 and a reduced cysteine residue at position 106, and oxidized-HMGB1 in which the three cysteine residues at positions 23, 45 and 106 have been oxidized to sulfonates; and

wherein said biological sample is obtained from the same human subject at different times relevant to assess the state of progression of said HIV infection and wherein an increase over time of the level of specific antibodies for said at least one redox form of HMGB1 reflects the state of progression of said HIV infection.